MedTrace Logo

Duration of ColdZyme® II

NCT03901846 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2019-10-11

No results posted yet for this study

Summary

The objective of this investigation is to verify that ColdZyme® is deposited onto the throat and estimate the half-life of the ColdZyme® solution in the oropharynx of human volunteers using a log-linear mixed-effects model (LMM).

Conditions

  • Common Cold

Interventions

DEVICE

ColdZyme

ColdZyme is a Class I medical device (CE-marked) with the following composition: glycerol, water, Tris buffer, CaCl2, menthol and trypsin

Sponsors & Collaborators

  • Enzymatica AB

    lead INDUSTRY

Principal Investigators

  • Bardur Sigurgeirsson, MD, PhD · Cutis Clinical Research Center (CCRC)

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-07
Primary Completion
2019-07-25
Completion
2019-07-25

Countries

  • Iceland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03901846 on ClinicalTrials.gov